From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema.

Randomised clinical trials (RCTs) are generally considered the gold-standard for providing scientific evidence for treatments' effectiveness and safety but their findings may not always be generalisable to the broader population treated in routine clinical practice. RCTs include highly selected patient populations that fit specific inclusion and exclusion criteria. Although they may have a lower level of certainty than RCTs on the evidence hierarchy, real-world data (RWD), such as observational studies, registries and databases, provide real-world evidence (RWE) that can complement RCTs. For example, RWE may help satisfy requirements for a new indication of an already approved drug and help us better understand long-term treatment effectiveness, safety and patterns of use in clinical practice. Many countries have set up registries, observational studies and databases containing information on patients with retinal diseases, such as diabetic macular oedema (DMO). These DMO RWD have produced significant clinical evidence in the past decade that has changed the management of DMO. RWD and medico-administrative databases are a useful resource to identify low frequency safety signals. They often have long-term follow-up with a large number of patients and minimal exclusion criteria. We will discuss improvements in healthcare information exchange technologies, such as blockchain technology and FHIR (Fast Healthcare Interoperability Resources), which will connect and extend databases already available. These registries can be linked with existing or emerging retinal imaging modalities using artificial intelligence to aid diagnosis, treatment decisions and provide prognostic information. The results of RCTs and RWE are combined to provide evidence-based guidelines.
Competing Interests: Declaration of competing interest PHG: consultant for Novartis, Bayer, Roche, Horus Pharma and Zeiss; HM: consultant for Allergan/Abbvie, Bayer, Novartis and Roche; DB: received research grants and travel expenses for Bayer and Novartis and consultant for Alcon; VD: consultant for Horus Pharma and Théa Pharma; VN: None; MG: received grants from NHMRC, grants from RANZCO Eye Foundation, grants and others from Novartis, and grants and others from Bayer; CCG: consultant for Allergan/AbbVie, Bayer, Horus Pharma, Novartis, Roche, Alcon and Théa Pharma.
(Copyright © 2023. Published by Elsevier Ltd.)